Literature DB >> 30801635

Trends in Incidence of Methicillin-resistant Staphylococcus aureus Bloodstream Infections Differ by Strain Type and Healthcare Exposure, United States, 2005-2013.

Isaac See1, Yi Mu1, Valerie Albrecht1, Maria Karlsson1, Ghinwa Dumyati2, Dwight J Hardy2, Mackenzie Koeck3, Ruth Lynfield3, Joelle Nadle4, Susan M Ray5, William Schaffner6, Alexander J Kallen1.   

Abstract

BACKGROUND: Previous reports suggested that US methicillin-resistant Staphylococcus aureus (MRSA) strain epidemiology has changed since the rise of USA300 MRSA. We describe invasive MRSA trends by strain type.
METHODS: Data came from 5 Centers for Disease Control and Prevention Emerging Infections Program sites conducting population-based surveillance and collecting isolates for invasive MRSA (ie, from normally sterile body sites), 2005-2013. MRSA bloodstream infection (BSI) incidence per 100 000 population was stratified by strain type and epidemiologic classification of healthcare exposures. Invasive USA100 vs USA300 case characteristics from 2013 were compared through logistic regression.
RESULTS: From 2005 to 2013, USA100 incidence decreased most notably for hospital-onset (6.1 vs 0.9/100 000 persons, P < .0001) and healthcare-associated, community-onset (10.7 vs 4.9/100 000 persons, P < .0001) BSIs. USA300 incidence for hospital-onset BSIs also decreased (1.5 vs 0.6/100 000 persons, P < .0001). However, USA300 incidence did not significantly change for healthcare-associated, community-onset (3.9 vs 3.3/100 000 persons, P = .05) or community-associated BSIs (2.5 vs 2.4/100 000 persons, P = .19). Invasive MRSA was less likely to be USA300 in patients who were older (adjusted odds ratio [aOR], 0.97 per year [95% confidence interval {CI}, .96-.98]), previously hospitalized (aOR, 0.36 [95% CI, .24-.54]), or had central lines (aOR, 0.44 [95% CI, .27-.74]), and associated with USA300 in people who inject drugs (aOR, 4.58 [95% CI, 1.16-17.95]).
CONCLUSIONS: Most of the decline in MRSA BSIs was from decreases in USA100 BSI incidence. Prevention of USA300 MRSA BSIs in the community will be needed to further reduce burden from MRSA BSIs. Published by Oxford University Press for the Infectious Diseases Society of America 2019.

Entities:  

Keywords:  MRSA; bloodstream infections; epidemiology; infection control; strains

Mesh:

Year:  2020        PMID: 30801635      PMCID: PMC6708714          DOI: 10.1093/cid/ciz158

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  27 in total

1.  Methicillin-resistant Staphylococcus aureus disease in three communities.

Authors:  Scott K Fridkin; Jeffrey C Hageman; Melissa Morrison; Laurie Thomson Sanza; Kathryn Como-Sabetti; John A Jernigan; Kathleen Harriman; Lee H Harrison; Ruth Lynfield; Monica M Farley
Journal:  N Engl J Med       Date:  2005-04-07       Impact factor: 91.245

2.  National estimates of central line-associated bloodstream infections in critical care patients.

Authors:  Matthew E Wise; R Douglas Scott; James M Baggs; Jonathan R Edwards; Katherine D Ellingson; Scott K Fridkin; L Clifford McDonald; John A Jernigan
Journal:  Infect Control Hosp Epidemiol       Date:  2013-04-18       Impact factor: 3.254

3.  Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.

Authors:  Seema Jain; Wesley H Self; Richard G Wunderink; Sherene Fakhran; Robert Balk; Anna M Bramley; Carrie Reed; Carlos G Grijalva; Evan J Anderson; D Mark Courtney; James D Chappell; Chao Qi; Eric M Hart; Frank Carroll; Christopher Trabue; Helen K Donnelly; Derek J Williams; Yuwei Zhu; Sandra R Arnold; Krow Ampofo; Grant W Waterer; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Jonathan A McCullers; Andrew T Pavia; Kathryn M Edwards; Lyn Finelli
Journal:  N Engl J Med       Date:  2015-07-14       Impact factor: 91.245

4.  Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk.

Authors:  B C Herold; L C Immergluck; M C Maranan; D S Lauderdale; R E Gaskin; S Boyle-Vavra; C D Leitch; R S Daum
Journal:  JAMA       Date:  1998-02-25       Impact factor: 56.272

Review 5.  Life After USA300: The Rise and Fall of a Superbug.

Authors:  Paul J Planet
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

6.  Health care-associated invasive MRSA infections, 2005-2008.

Authors:  Alexander J Kallen; Yi Mu; Sandra Bulens; Arthur Reingold; Susan Petit; Ken Gershman; Susan M Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; John M Townes; William Schaffner; Priti R Patel; Scott K Fridkin
Journal:  JAMA       Date:  2010-08-11       Impact factor: 56.272

7.  Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007.

Authors:  Deron C Burton; Jonathan R Edwards; Teresa C Horan; John A Jernigan; Scott K Fridkin
Journal:  JAMA       Date:  2009-02-18       Impact factor: 56.272

8.  Characterization of methicillin-resistant Staphylococcus aureus isolates collected in 2005 and 2006 from patients with invasive disease: a population-based analysis.

Authors:  Brandi Limbago; Gregory E Fosheim; Valerie Schoonover; Christina E Crane; Joelle Nadle; Susan Petit; David Heltzel; Susan M Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; John M Townes; William Schaffner; Yi Mu; Scott K Fridkin
Journal:  J Clin Microbiol       Date:  2009-03-25       Impact factor: 5.948

9.  Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database.

Authors:  Linda K McDougal; Christine D Steward; George E Killgore; Jasmine M Chaitram; Sigrid K McAllister; Fred C Tenover
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

10.  Invasive Methicillin-Resistant Staphylococcus aureus USA500 Strains from the U.S. Emerging Infections Program Constitute Three Geographically Distinct Lineages.

Authors:  M B Frisch; S Castillo-Ramírez; R A Petit; M M Farley; S M Ray; V S Albrecht; B M Limbago; J Hernandez; I See; S W Satola; T D Read
Journal:  mSphere       Date:  2018-05-02       Impact factor: 4.389

View more
  14 in total

1.  Bacteriological Profile and Antimicrobial Susceptibility Patterns of Gram-Negative Bloodstream Infection and Risk Factors Associated with Mortality and Drug Resistance: A Retrospective Study from Shanxi, China.

Authors:  Nan Shi; Jianbang Kang; Shuyun Wang; Yan Song; Donghong Yin; Xiaoxia Li; Qian Guo; Jinju Duan; Shuqiu Zhang
Journal:  Infect Drug Resist       Date:  2022-07-06       Impact factor: 4.177

2.  Identifying patient-level risk factors associated with non-β-lactam resistance outcomes in invasive MRSA infections in the United States using chain graphs.

Authors:  William J Love; C Annie Wang; Cristina Lanzas
Journal:  JAC Antimicrob Resist       Date:  2022-07-05

3.  Investigation of Hospital-Onset Methicillin-Resistant Staphylococcus aureus Bloodstream Infections at Eight High Burden Acute Care Facilities in the United States, 2016.

Authors:  D Cal Ham; Isaac See; Shannon Novosad; Matthew Crist; Garrett Mahon; Lucy Fike; Kevin Spicer; Pamela Talley; Andrea Flinchum; Marion Kainer; Alexander J Kallen; Maroya Spalding Walters
Journal:  J Hosp Infect       Date:  2020-04-10       Impact factor: 3.926

4.  Decreased Incidence of Methicillin-Resistant Staphylococcus aureus Bacteremia in Intensive Care Units: a 10-Year Clinical, Microbiological, and Genotypic Analysis in a Tertiary Hospital.

Authors:  Haein Kim; Eun Sil Kim; Seung Cheol Lee; Eunmi Yang; Hee Sueng Kim; Heungsup Sung; Mi-Na Kim; Jiwon Jung; Min Jae Kim; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jun Hee Woo; Yang Soo Kim; Yong Pil Chong
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

5.  Vital Signs: Trends in Staphylococcus aureus Infections in Veterans Affairs Medical Centers - United States, 2005-2017.

Authors:  Makoto Jones; John A Jernigan; Martin E Evans; Gary A Roselle; Kelly M Hatfield; Matthew H Samore
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-03-08       Impact factor: 17.586

6.  Construction of A New Dose-Response Model for Staphylococcus aureus Considering Growth and Decay Kinetics on Skin.

Authors:  Elaheh Esfahanian; Umesh Adhikari; Kirk Dolan; Jade Mitchell
Journal:  Pathogens       Date:  2019-11-21

7.  Development of a Staphylococcus aureus reporter strain with click beetle red luciferase for enhanced in vivo imaging of experimental bacteremia and mixed infections.

Authors:  Robert J Miller; Heidi A Crosby; Katrin Schilcher; Yu Wang; Roger V Ortines; Momina Mazhar; Dustin A Dikeman; Bret L Pinsker; Isabelle D Brown; Daniel P Joyce; Jeffrey Zhang; Nathan K Archer; Haiyun Liu; Martin P Alphonse; Julie Czupryna; William R Anderson; Nicholas M Bernthal; Lea Fortuno-Miranda; Jeff W M Bulte; Kevin P Francis; Alexander R Horswill; Lloyd S Miller
Journal:  Sci Rep       Date:  2019-11-13       Impact factor: 4.379

8.  Human monoclonal antibodies against Staphylococcus aureus surface antigens recognize in vitro and in vivo biofilm.

Authors:  Lisanne de Vor; Bruce van Dijk; Kok van Kessel; Jeffrey S Kavanaugh; Carla de Haas; Piet C Aerts; Marco C Viveen; Edwin C Boel; Ad C Fluit; Jakub M Kwiecinski; Gerard C Krijger; Ruud M Ramakers; Freek J Beekman; Ekaterina Dadachova; Marnix Geh Lam; H Charles Vogely; Bart Ch van der Wal; Jos Ag van Strijp; Alexander R Horswill; Harrie Weinans; Suzan Hm Rooijakkers
Journal:  Elife       Date:  2022-01-06       Impact factor: 8.140

9.  Contemporary Clinical Isolates of Staphylococcus aureus from Pediatric Osteomyelitis Patients Display Unique Characteristics in a Mouse Model of Hematogenous Osteomyelitis.

Authors:  Philip M Roper; Kara R Eichelberger; Linda Cox; Luke O'Connor; Christine Shao; Caleb A Ford; Stephanie A Fritz; James E Cassat; Deborah J Veis
Journal:  Infect Immun       Date:  2021-06-07       Impact factor: 3.441

10.  Bloodstream infections in critically ill patients: an expert statement.

Authors:  Jean-François Timsit; Etienne Ruppé; François Barbier; Alexis Tabah; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2020-02-11       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.